These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 26542177)
1. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177 [TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276 [TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321 [TBL] [Abstract][Full Text] [Related]
5. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830 [TBL] [Abstract][Full Text] [Related]
6. A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. Paccapelo A; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Santoni M; Bonizzoni E; Perrone T; Scoccianti S J Transl Med; 2012 May; 10():90. PubMed ID: 22583678 [TBL] [Abstract][Full Text] [Related]
7. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471 [TBL] [Abstract][Full Text] [Related]
8. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. Minniti G; Agolli L; Falco T; Scaringi C; Lanzetta G; Caporello P; Osti MF; Esposito V; Enrici RM J Neurooncol; 2015 May; 122(3):559-66. PubMed ID: 25702193 [TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523 [TBL] [Abstract][Full Text] [Related]
10. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas]. Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763 [TBL] [Abstract][Full Text] [Related]
11. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience. Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296 [No Abstract] [Full Text] [Related]
12. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476 [TBL] [Abstract][Full Text] [Related]
13. Retrospective study of nivolumab for patients with recurrent high grade gliomas. Mantica M; Pritchard A; Lieberman F; Drappatz J J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086 [TBL] [Abstract][Full Text] [Related]
14. Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. Vaccaro V; Fabi A; Vidiri A; Giannarelli D; Metro G; Telera S; Vari S; Piludu F; Carosi MA; Villani V; Cognetti F; Pompili A; Marucci L; Carapella CM; Pace A Biomed Res Int; 2014; 2014():351252. PubMed ID: 24877084 [TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233 [TBL] [Abstract][Full Text] [Related]
16. Cystemustine in recurrent high grade glioma. Durando X; Thivat E; Roché H; Bay JO; Lemaire JJ; Verrelle P; Chazal J; Curé H; Chollet P J Neurooncol; 2006 Aug; 79(1):33-7. PubMed ID: 16575534 [TBL] [Abstract][Full Text] [Related]
17. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. Beauchesne PD; Taillandier L; Bernier V; Carnin C Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662 [TBL] [Abstract][Full Text] [Related]
18. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692 [No Abstract] [Full Text] [Related]
19. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Frenay M; Giroux B; Khoury S; Derlon JM; Namer M Eur J Cancer; 1991; 27(7):852-6. PubMed ID: 1834116 [TBL] [Abstract][Full Text] [Related]
20. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]